COR-001

DRUG2 trials

Sponsors

Novo Nordisk A/S, University of Colorado, Denver

Conditions

AnemiaChronic Kidney Diseases

Phase 1

Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of COR-001

CompletedNCT02868229

Novo Nordisk A/SAnemia

Start: 2016-09-12End: 2018-12-11Updated: 2021-07-30

A Study of Patients With Chronic Kidney Disease to Assess the Safety of a Single Dose of COR-001

CompletedNCT03126318

University of Colorado, DenverChronic Kidney Diseases

Start: 2017-05-19End: 2019-12-19Updated: 2020-09-09

Related Papers

Effect of Ziltivekimab on Determinants of Hemoglobin in Patients with CKD Stage 3–5: An Analysis of a Randomized Trial (RESCUE)

Journal of the American Society of Nephrology2023-12-1318 citations

Ziltivekimab for Treatment of Anemia of Inflammation in Patients on Hemodialysis: Results from a Phase 1/2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Journal of the American Society of Nephrology2020-12-0371 citations